Q2 EPS Estimate for Blueprint Medicines Boosted by Analyst

Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Stock analysts at Zacks Research boosted their Q2 2025 EPS estimates for shares of Blueprint Medicines in a research note issued on Wednesday, May 21st. Zacks Research analyst A. Chakraborty now forecasts that the biotechnology company will post earnings per share of ($0.59) for the quarter, up from their prior estimate of ($0.64). The consensus estimate for Blueprint Medicines' current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Blueprint Medicines' Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($2.08) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.12 EPS, FY2026 earnings at $0.28 EPS and FY2027 earnings at $2.79 EPS.

Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. boosted their price objective on shares of Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Wedbush reaffirmed an "outperform" rating and set a $128.00 price target on shares of Blueprint Medicines in a research report on Thursday, May 1st. Needham & Company LLC reduced their price objective on shares of Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating on the stock in a research note on Monday, April 28th. Wall Street Zen raised shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a report on Friday, May 2nd. Finally, Jefferies Financial Group started coverage on shares of Blueprint Medicines in a research report on Monday, March 17th. They issued a "buy" rating and a $135.00 target price for the company. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $126.56.

Blueprint Medicines Stock Performance

NASDAQ BPMC traded down $1.44 during trading on Monday, reaching $100.06. The company's stock had a trading volume of 709,926 shares, compared to its average volume of 781,125. The firm has a market cap of $6.46 billion, a price-to-earnings ratio of -92.65 and a beta of 0.83. The business's fifty day moving average price is $91.23 and its 200-day moving average price is $94.62. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. Blueprint Medicines has a twelve month low of $73.04 and a twelve month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The company had revenue of $149.41 million for the quarter, compared to analysts' expectations of $158.31 million. During the same period in the prior year, the company posted $1.40 EPS. The firm's revenue was up 55.5% compared to the same quarter last year.

Hedge Funds Weigh In On Blueprint Medicines

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Blueprint Medicines by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 6,774,884 shares of the biotechnology company's stock valued at $590,905,000 after purchasing an additional 91,450 shares during the period. Price T Rowe Associates Inc. MD increased its position in Blueprint Medicines by 5.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,679,089 shares of the biotechnology company's stock worth $495,331,000 after acquiring an additional 291,822 shares during the period. Wellington Management Group LLP increased its position in Blueprint Medicines by 8.0% during the fourth quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock worth $373,421,000 after acquiring an additional 316,754 shares during the period. William Blair Investment Management LLC increased its position in Blueprint Medicines by 16.1% during the fourth quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company's stock worth $169,616,000 after acquiring an additional 269,896 shares during the period. Finally, Geode Capital Management LLC increased its position in Blueprint Medicines by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 1,490,101 shares of the biotechnology company's stock worth $129,996,000 after acquiring an additional 9,914 shares during the period.

Insider Buying and Selling

In other news, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $95.02, for a total value of $216,075.48. Following the transaction, the chief operating officer now owns 69,266 shares of the company's stock, valued at $6,581,655.32. This trade represents a 3.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Ariel Hurley sold 3,203 shares of Blueprint Medicines stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the completion of the transaction, the insider now directly owns 18,270 shares in the company, valued at approximately $1,692,167.40. This represents a 14.92% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,777 shares of company stock worth $1,256,490. 4.21% of the stock is owned by company insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.